Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 183

Related Citations for PubMed (Select 23401459)

1.

Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J.

J Clin Oncol. 2013 Mar 20;31(9):1164-71. doi: 10.1200/JCO.2012.44.0693. Epub 2013 Feb 11.

2.

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.

Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW.

Cancer. 2013 Oct 15;119(20):3662-71. doi: 10.1002/cncr.28243. Epub 2013 Aug 6.

3.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
4.

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozák T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH.

J Clin Oncol. 2013 May 1;31(13):1624-30. doi: 10.1200/JCO.2012.47.1862. Epub 2013 Apr 1.

5.

Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, Jarosinska RJ, Schmid C, Finke J, Stevens WB, Schouten HC, Kaufmann M, Sebban C, Trneny M, Kobbe G, Fornecker LM, Schetelig J, Kanfer E, Heinicke T, Pfreundschuh M, Diez-Martin JL, Bordessoule D, Robinson S, Dreger P.

Ann Oncol. 2014 May;25(5):1053-8. doi: 10.1093/annonc/mdu097. Epub 2014 Feb 27.

PMID:
24585719
6.

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS.

Haematologica. 2011 Aug;96(8):1128-35. doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12.

7.

Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.

Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P.

J Clin Oncol. 2012 Jun 20;30(18):2211-7. doi: 10.1200/JCO.2011.37.4108. Epub 2012 Apr 30.

8.

A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.

Stewart DA, Duan Q, Carlson L, Russell JA, Bahlis NJ, Duggan P, Hasegawa W, Voralia M.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):475-82. doi: 10.1016/j.clml.2011.06.012. Epub 2011 Aug 10.

PMID:
21831743
9.

Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy.

Bains P, Al Tourah A, Campbell BA, Pickles T, Gascoyne RD, Connors JM, Savage KJ.

Ann Oncol. 2013 Feb;24(2):428-32. doi: 10.1093/annonc/mds433. Epub 2012 Oct 3.

10.

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.

Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW.

Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20.

PMID:
24111533
12.

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A.

Br J Haematol. 2003 Aug;122(3):457-64.

PMID:
12877674
13.
14.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ.

Biol Blood Marrow Transplant. 2003 Oct;9(10):649-56.

PMID:
14569561
15.

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, Solal-Céligny P, Coiffier B.

J Clin Oncol. 2008 Jul 20;26(21):3614-20. doi: 10.1200/JCO.2007.15.5358. Epub 2008 Jun 16.

16.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.

Villa D, George A, Seymour JF, Toze CL, Crump M, Lee C, Buckstein R, Stewart DA, MacDonald D, Foley R, Xenocostas A, Sabloff M, Chua N, Couture F, Larouche JF, Cohen S, Savage KJ, Connors JM, Panzarella T, Carney DA, Dickinson M, Kuruvilla J.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1813-8. doi: 10.1016/j.bbmt.2014.07.015. Epub 2014 Jul 18.

PMID:
25042735
17.

High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.

Stein RS, Greer JP, Goodman S, Kallianpur A, Ahmed MS, Wolff SN.

Bone Marrow Transplant. 1999 Feb;23(3):227-33.

18.

Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.

Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H.

Eur J Haematol. 2000 Jul;65(1):17-22.

PMID:
10914935
19.

Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.

Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW.

Biol Blood Marrow Transplant. 2006 Sep;12(9):965-72.

PMID:
16920563
20.

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.

Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Berinstein NL.

Ann Oncol. 2004 Feb;15(2):283-90.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk